Date of this Version
Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2) are both autosomal dominant tumor disorders that are caused by mutations in different genes. Individuals with NF1 develop neurofibromas and Malignant Peripheral Nerve Sheath Tumors (MPNSTs), while individuals with NF2 primarily develop tumors of Schwann cells. Mutations in NF1 cause hyper-activation of the RAS/RAF/MEK/ERK pathway. This pathway is one of the most commonly activated cancer signals. Inhibitors of pathway components RAF and MEK are now approved to treat melanoma, which is an aggressive form of tumor associated with NF1 mutations. Promising clinical results with the neurofibromas of NF1 patients have been reported with MEK inhibitors. However, clinical experience with melanomas show that malignant tumors become resistant to MEK inhibitors after a few months and tumors recur. Little is known about resistance to MEK inhibitors in NF1 tumors. Here, the mechanisms of adaption that occurred in the acquisition of MEK resistance by NF1 cells have been investigated to facilitate the design of long-term therapeutic strategies. Two MEK resistant NF1 cell lines were developed and screened extensively against a large variety of individual drugs and two-drug combinations to identify compensating signals. Two pathways that synergized with a MEK inhibitor were identified and examined. The first was the Hippo-YAP signaling pathway and the second was the receptor tyrosine kinase DDR1. Hippo-YAP signaling was upregulated in MEK resistant MPNST cells, suggesting a mechanism for the increased synergy of Hippo inhibitors when used in combination with MEK inhibitors and the increased expression levels of its target genes. Similarly, DDR1 was upregulated in MEK resistant cells, suggesting DDR1 expression is regulated by a common mechanism as Hippo-YAP signaling. Interestingly, the MEK resistant NF1 cells resembled NF2 cells in their appearance and their Hippo/MEK inhibitor synergy suggesting that NF1 cells become more dependent on NF2 signaling pathways when they become MEK inhibitor resistant.
Neurofibromatosis Type 1 and 2, High Throughput screen, Hippo signaling, drug combination screen, resistance
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.
Available for download on Saturday, May 20, 2023
Cancer Biology Commons, Chemical and Pharmacologic Phenomena Commons, Chemistry Commons, Complex Mixtures Commons, Nervous System Diseases Commons, Other Chemicals and Drugs Commons, Pharmacology Commons
Date Posted: 28 May 2019